SE539450C2 - Imatinib for use in the treatment of stroke - Google Patents

Imatinib for use in the treatment of stroke Download PDF

Info

Publication number
SE539450C2
SE539450C2 SE1650260A SE1650260A SE539450C2 SE 539450 C2 SE539450 C2 SE 539450C2 SE 1650260 A SE1650260 A SE 1650260A SE 1650260 A SE1650260 A SE 1650260A SE 539450 C2 SE539450 C2 SE 539450C2
Authority
SE
Sweden
Prior art keywords
imatinib
patient
stroke
administered
dose
Prior art date
Application number
SE1650260A
Other languages
English (en)
Swedish (sv)
Other versions
SE1650260A1 (en
Inventor
Eriksson Ulf
Gunnar Wahlgren Nils
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to SE1650260A priority Critical patent/SE539450C2/en
Priority to HRP20211621TT priority patent/HRP20211621T1/hr
Priority to AU2017227515A priority patent/AU2017227515B2/en
Priority to SI201730931T priority patent/SI3423060T1/sl
Priority to PT177603990T priority patent/PT3423060T/pt
Priority to EP17760399.0A priority patent/EP3423060B1/en
Priority to CN201780013732.6A priority patent/CN108697711A/zh
Priority to ES17760399T priority patent/ES2895432T3/es
Priority to JP2018545843A priority patent/JP6914957B2/ja
Priority to PCT/SE2017/050183 priority patent/WO2017151043A1/en
Priority to PL17760399T priority patent/PL3423060T3/pl
Priority to RU2019122730A priority patent/RU2739382C1/ru
Priority to CN202411509669.3A priority patent/CN119523986A/zh
Priority to RS20211286A priority patent/RS62465B1/sr
Priority to LTEPPCT/SE2017/050183T priority patent/LT3423060T/lt
Priority to US16/080,529 priority patent/US10953010B2/en
Priority to DK17760399.0T priority patent/DK3423060T3/da
Priority to HUE17760399A priority patent/HUE056798T2/hu
Publication of SE1650260A1 publication Critical patent/SE1650260A1/en
Publication of SE539450C2 publication Critical patent/SE539450C2/en
Priority to US17/186,303 priority patent/US20210236488A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE1650260A 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke SE539450C2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke
PCT/SE2017/050183 WO2017151043A1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke
PL17760399T PL3423060T3 (pl) 2016-02-29 2017-02-27 Imatynib do stosowania w leczeniu udaru mózgu
SI201730931T SI3423060T1 (sl) 2016-02-29 2017-02-27 Imatinib za uporabo pri zdravljenju možganske kapi
PT177603990T PT3423060T (pt) 2016-02-29 2017-02-27 Imatinib para utilização no tratamento de acidente vascular cerebral
EP17760399.0A EP3423060B1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke
CN201780013732.6A CN108697711A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途
ES17760399T ES2895432T3 (es) 2016-02-29 2017-02-27 Imatinib para uso en el tratamiento de accidente cerebrovascular
JP2018545843A JP6914957B2 (ja) 2016-02-29 2017-02-27 脳卒中の処置における使用のためのイマチニブ
HRP20211621TT HRP20211621T1 (hr) 2016-02-29 2017-02-27 Imatinib za uporabu u liječenju moždanog udara
AU2017227515A AU2017227515B2 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke
RU2019122730A RU2739382C1 (ru) 2016-02-29 2017-02-27 Иматиниб для применения для лечения инсульта
CN202411509669.3A CN119523986A (zh) 2016-02-29 2017-02-27 伊马替尼在治疗中风中的用途
RS20211286A RS62465B1 (sr) 2016-02-29 2017-02-27 Imatinib za upotrebu u lečenju moždanog udara
LTEPPCT/SE2017/050183T LT3423060T (lt) 2016-02-29 2017-02-27 Imatinibas, skirtas naudoti insulto gydymui
US16/080,529 US10953010B2 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke
DK17760399.0T DK3423060T3 (da) 2016-02-29 2017-02-27 Imatinib til anvendelse til behandling af slagtilfælde
HUE17760399A HUE056798T2 (hu) 2016-02-29 2017-02-27 Imatinib stroke kezelésében való alkalmazásra
US17/186,303 US20210236488A1 (en) 2016-02-29 2021-02-26 Imatinib for use in the treatment of stroke

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke

Publications (2)

Publication Number Publication Date
SE1650260A1 SE1650260A1 (en) 2017-08-30
SE539450C2 true SE539450C2 (en) 2017-09-26

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke

Country Status (17)

Country Link
US (2) US10953010B2 (cg-RX-API-DMAC7.html)
EP (1) EP3423060B1 (cg-RX-API-DMAC7.html)
JP (1) JP6914957B2 (cg-RX-API-DMAC7.html)
CN (2) CN108697711A (cg-RX-API-DMAC7.html)
AU (1) AU2017227515B2 (cg-RX-API-DMAC7.html)
DK (1) DK3423060T3 (cg-RX-API-DMAC7.html)
ES (1) ES2895432T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056798T2 (cg-RX-API-DMAC7.html)
LT (1) LT3423060T (cg-RX-API-DMAC7.html)
PL (1) PL3423060T3 (cg-RX-API-DMAC7.html)
PT (1) PT3423060T (cg-RX-API-DMAC7.html)
RS (1) RS62465B1 (cg-RX-API-DMAC7.html)
RU (1) RU2739382C1 (cg-RX-API-DMAC7.html)
SE (1) SE539450C2 (cg-RX-API-DMAC7.html)
SI (1) SI3423060T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151043A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
CN118524852A (zh) * 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2007124308A2 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2008051597A1 (en) * 2006-10-26 2008-05-02 Sicor Inc. Process for the preparation of imatinib
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
HUE044688T2 (hu) * 2009-03-27 2019-11-28 Moleac Pte Ltd Terápia sejtnövekedés elõsegítésére

Also Published As

Publication number Publication date
US20190030030A1 (en) 2019-01-31
PL3423060T3 (pl) 2022-01-10
EP3423060B1 (en) 2021-07-21
SE1650260A1 (en) 2017-08-30
AU2017227515A1 (en) 2018-08-30
EP3423060A1 (en) 2019-01-09
LT3423060T (lt) 2021-11-10
EP3423060A4 (en) 2020-01-01
PT3423060T (pt) 2021-10-20
ES2895432T3 (es) 2022-02-21
HRP20211621T1 (hr) 2022-02-04
AU2017227515B2 (en) 2022-03-24
JP2019507165A (ja) 2019-03-14
RS62465B1 (sr) 2021-11-30
SI3423060T1 (sl) 2021-11-30
DK3423060T3 (da) 2021-10-25
HUE056798T2 (hu) 2022-03-28
RU2739382C1 (ru) 2020-12-23
CN108697711A (zh) 2018-10-23
US10953010B2 (en) 2021-03-23
JP6914957B2 (ja) 2021-08-04
WO2017151043A1 (en) 2017-09-08
CN119523986A (zh) 2025-02-28
US20210236488A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US20210236488A1 (en) Imatinib for use in the treatment of stroke
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
JP7082115B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
Polifka Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence
Du et al. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
AU2007218709A1 (en) Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke
Awad et al. Dabigatran, intracranial hemorrhage, and the neurosurgeon
RU2542455C2 (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
Guo et al. Clinical efficacy and prognosis of aspirin combined with clopidogrel in patients with cerebral hemorrhage after operation.
RU2845317C1 (ru) Способ лечения постковидного синдрома
Tempaku Intracranial hemorrhage during administration of a novel oral anticoagulant
AL SHAMSI et al. WCN23-0109 MANAGEMENT OF ASYMPTOMATIC ANGIOMYOLIPOMA IN PREGNANCY
Naeem et al. Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism
CN115475165B (zh) 马来酸茚达特罗在出血性脑损伤相关疾病中的应用
ALLAM WCN23-0127 KIDNEY OUT COMES IN SUDANSES CHILDREN WITH LUPUS NEPHRITIES
Wang et al. Pre-operative Embolization of a Cerebellar Hemangioblastoma Using Polyvinyl Alcohol (PVA) and Target Tetra 360 Detachable Coil
Alkanat et al. Dermatologic Reactions Following COVID-19 Vaccination: A Case Series.
Wang et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial
Steglatro New Drug Approvals
IVH Special Disease Management
KR20250114057A (ko) 맥관 기형용 의약 조성물 및 맥관 기형의 치료 방법
Katayoun Vahedi Surgery for acute ischemic stroke
US20180243247A1 (en) Drug combinations for cerebrovascular disease
Rahman et al. Effect of Tamsulosin on Treatment of Lower Ureteric Calculi
RU2578472C1 (ru) Способ лечения злокачественной опухоли головного мозга

Legal Events

Date Code Title Description
NUG Patent has lapsed